Skip to content

Strata Oncology

Request correction

Strata Oncology is a precision oncology company in Ann Arbor, United States, developing algorithmic biomarkers for antibody-drug conjugates and immunotherapy.

Last updated September 16, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Strata Oncology is a precision oncology company based in Ann Arbor, United States. Its mission is to accelerate the impact of precision medicine for patients with cancer. The company develops advanced algorithmic biomarkers for antibody-drug conjugates (ADCs) and immunotherapy, including Antibody-drug Conjugate Treatment Response Scores and an Immunotherapy Response Score. Dan Rhodes, PhD serves as Co-Founder & CEO, and Scott Tomlins, MD, PhD as Co-founder & Chief Medical Officer.

History

Strata Oncology is a company in Ann Arbor, United States. It describes itself as a next-generation precision oncology company enabling smarter cancer treatment so that every patient gets their best possible therapy. Its mission is to accelerate the impact of precision medicine for patients with cancer. The company develops advanced algorithmic biomarkers for antibody-drug conjugates and immunotherapy.

Products and positioning

Precision oncology; advanced algorithmic biomarkers for antibody-drug conjugates and immunotherapy

  • Antibody-drug Conjugate Treatment Response Scores

    Predictive biomarkers for benefit from a variety of approved and investigational antibody-drug conjugates (ADCs); based on a proprietary calculation method of three components including ADC target expression.

  • Immunotherapy Response Score

    A pan-solid tumor predictive diagnostic tool for anti-PD-1/PD-L1 monotherapy benefit. This biomarker algorithm combines tumor mutation burden (TMB) with quantitative expression of PD-L1, PD-1, ADAM12 and TOP2A.

Recent events

  • Unconfirmed

    Reported

    Strata Oncology raises $90 million in Series C funding[4]

    Strata Oncology announced that it had raised $90 million in a Series C financing round. The company said the proceeds would support development of its personalized minimal residual disease assay and RNA-based treatment selection tests.

  • Reported

    Strata Oncology launches Strata Assistant for Epic[5]

    Strata Oncology announced the launch of Strata Assistant for Epic, an app integrated with the Epic electronic medical record system to streamline StrataNGS test submission. Kettering Health Network was its first fully integrated user.

Read more

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/strata-oncology-united-states · Editorial policy · How profiles are compiled